Immunogenicity and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial

• Main Authors: Subhash Thuluva (Author), Vikram Paradkar (Author), SubbaReddy Gunneri (Author), Vijay Yerroju (Author), Rammohan Mogulla (Author), Pothakamuri Venkata Suneetha (Author), Kishore Turaga (Author), Mahesh Kyasani (Author), Senthil Kumar Manoharan (Author), Srikanth Adabala (Author), Aditya Sri Javvadi (Author), Guruprasad Medigeshi (Author), Janmejay Singh (Author), Heena Shaman (Author), Akshay Binayke (Author), Aymaan Zaheer (Author), Amit Awasthi (Author), Chandramani Singh (Author), Venkateshwar Rao A (Author), Indranil Basu (Author), Khobragade Akash Ashok Kumar (Author), Anil Kumar Pandey (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Optimum formulation of Biological-E's protein subunit CORBEVAX™ vaccine was selected in phase-1 and -2 studies and found to be safe and immunogenic in healthy adult population. This is a phase-3 prospective, single-blinded, randomized, active controlled study conducted at 18 sites across India...